ROGAINE EXTRA STRENGTH (FOR MEN)
Clinical safety rating
cautionComprehensive clinical and safety monograph for ROGAINE EXTRA STRENGTH (FOR MEN) (ROGAINE EXTRA STRENGTH (FOR MEN)).
Minoxidil is a potassium channel opener that hyperpolarizes vascular smooth muscle cells, leading to vasodilation. It also prolongs the anagen phase of hair follicles and increases hair follicle size, promoting hair growth.
| Metabolism | Minoxidil is primarily metabolized by conjugation with glucuronic acid at the N-oxide position in the liver. CYP450 enzymes are minimally involved. |
| Excretion | Renal excretion of unchanged drug and metabolites accounts for approximately 95% of elimination. Fecal excretion is minimal (<3%). |
| Half-life | Terminal elimination half-life is approximately 4.2 hours (range 3.5–5.0 hours) in healthy adults. Clinical context: Maintains steady-state concentrations with twice-daily topical application without significant accumulation. |
| Protein binding | Approximately 20% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Apparent volume of distribution is approximately 2.5 L/kg, indicating extensive distribution into total body water and tissues. |
| Bioavailability | Topical: systemic bioavailability is low (approximately 1.4% of applied dose) due to poor percutaneous absorption. Oral: approximately 50% (not indicated for this formulation). |
| Onset of Action | Topical: visible hair regrowth may be observed after 4–6 months of twice-daily application. Maximal response typically requires at least 12 months of continuous use. |
| Duration of Action | Duration of effect is dependent on continued application. Discontinuation results in reversal of hair regrowth within 3–6 months, returning to pretreatment baseline. |
| Molecular Weight | 209.25 |
1 mL of 5% minoxidil solution applied topically to the scalp twice daily.
| Dosage form | SOLUTION |
| Renal impairment | No dosage adjustment required for renal impairment; not systemically absorbed in significant amounts. |
| Liver impairment | No dosage adjustment required for hepatic impairment; not systemically absorbed in significant amounts. |
| Pediatric use | Safety and effectiveness in pediatric patients under 18 years have not been established. |
| Geriatric use | No specific dosage adjustment; use with caution due to potential for increased systemic absorption from thinner skin. |
| 1st trimester | Topical minoxidil is generally considered low risk in the first trimester due to minimal systemic absorption, but data are limited. Avoid unless clearly needed. |
| 2nd trimester | Limited data; systemic absorption is low. Use only if potential benefit justifies potential fetal risk. |
| 3rd trimester | Limited data; low systemic absorption suggests minimal risk. However, avoid systemic formulations. |
Clinical note
Comprehensive clinical and safety monograph for ROGAINE EXTRA STRENGTH (FOR MEN) (ROGAINE EXTRA STRENGTH (FOR MEN)).
| Placental transfer | Minoxidil crosses the placenta in animal studies; human data are limited. Topical application results in negligible systemic levels, reducing risk. |
| Breastfeeding | Minoxidil is excreted into breast milk in low amounts; topical use results in minimal systemic exposure. Monitor infant for possible effects such as fluid retention or hypotension, though unlikely. Use with caution. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Topical minoxidil (Rogaine Extra Strength) is minimally absorbed (approximately 1.4% of applied dose). Animal studies show no teratogenicity at systemic exposures up to 4 times the human dose. Human data are insufficient; risk is considered low but cannot be excluded. Use only if clearly needed during pregnancy. No specific trimester risks identified. |
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond routine prenatal care. Monitor maternal blood pressure if large areas of damaged skin are treated due to potential increased absorption. |
| Fertility Effects | No adverse effects on fertility have been reported in animal studies or human data with topical minoxidil. Systemic exposure is minimal and unlikely to affect reproductive function. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
Hypersensitivity to minoxidil or any component of the formulation
| Precautions | Cardiovascular risks such as tachycardia, fluid retention, and pericardial effusion with topical use are rare but possible., May cause hypotension if accidentally ingested., Avoid contact with eyes and broken skin., Discontinue if scalp irritation occurs., Use with caution in patients with hypertension or underlying cardiovascular disease. |
| Food/Dietary | No known food interactions. |
| Clinical Pearls | Rogaine Extra Strength (5% minoxidil) is indicated for androgenetic alopecia in men. Onset of hair regrowth typically occurs after at least 4 months of twice-daily use; continued use is required to maintain effects. Discontinue if scalp irritation or unwanted facial hair growth occurs. Not effective for receding frontal hairline; primarily promotes vertex balding. May cause initial shedding of telogen hairs, which is a sign of efficacy. |
| Patient Advice | Apply 1 mL directly to the scalp in the affected area twice daily, not more often. · Wash hands thoroughly after each application. · Do not apply to wet hair or within 24 hours of using other scalp treatments. · Results may take 4 months or longer; continued use is necessary to maintain regrowth. · Initial hair shedding is normal and indicates new hair growth. · Avoid contact with eyes; if accidental contact occurs, rinse with cool water. |
Loading safety data…